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ABSTRACT 
The common cold is a significant cause of morbidity world-wide, with human 
rhinovirus infections accounting for a majority colds suffered each year.  While the 
symptoms of the common cold are generally mild and self-limiting, vulnerable 
populations such as individuals with asthma can experience severe secondary 
complications including acute asthma exacerbation which can result in severe morbidity.  
Most human rhinovirus types utilize Intercellular Adhesion Molecule-1 (ICAM-1) as a 
receptor to enter cells and initiate infection.  Expression of this cell-surface protein is 
elevated in the respiratory tract of asthma patients.  The theoretical basis for this research 
is the observation that plasma measures of the soluble form of Intercellular Adhesion 
Molecule-1 (sICAM-1) decrease in response to vitamin C supplementation.  As 
rhinovirus infection occurs in the upper respiratory tract, the primary aim of this study 
was to evaluate change in sICAM-1 concentration in nasal lavage of asthmatic 
individuals in response to vitamin C supplementation.  Otherwise healthy asthmatic 
adults between the ages of 18-65 years who were not currently using steroidal nasal 
sprays, smoking, or actively training for competitive sports were recruited from a 
university community and surrounding area to participate in an 18-day double-blind 
randomized placebo-controlled supplement study with a parallel arm design.  13 subjects 
were stratified based on age, gender, BMI and baseline plasma vitamin C level to receive 
either 500 mg vitamin C twice daily (VTC, n=7) or placebo (PLC, n=6).  Biochemical 
measures included nasal lavage sICAM-1, plasma sICAM-1, plasma histamine, and 
plasma vitamin C.  Survey measures included Wisconsin Upper Respiratory Symptom 
Survey-21 to assess colds, Daytime Symptom Diary Scale to assess asthma symptoms, 
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and measures of diet quality including a vitamin C food frequency questionnaire and 
Rapid Eating Assessment for Participants.  No between group comparison of means 
reached significance (Mann-Whitney U test, p>0.05).  Nasal lavage sICAM-1 levels were 
decreased in VTC group by 37% at study day 4, although this finding did not reach 
significance.  Findings in this study can be used to develop future investigations into the 
response of nasal lavage sICAM-1 to vitamin C supplementation. 
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CHAPTER 1 
INTRODUCTION 
 
The common cold is one of the most significant causes of morbidity world-wide, 
with human rhinovirus infections accounting for 50-80% of all colds endured by people 
each year (Mackay, 2008, 297-320).  While the symptoms associated with the common 
cold are generally mild and resolve within a few days, vulnerable populations can 
experience severe disease such as lower respiratory infection or serious secondary 
complications (Linsuwanon et al., 2009, 115-121; Message et al., 2008, 13562-13567).  
Acute asthma exacerbation is a serious complication of rhinovirus infection and can 
result in hospitalization and in extreme cases, fatality (Denlinger et al., 2011, 1007-1014; 
Ozcan et al., 2011, 888-893; Gavala, Bertics and Gern, 2011, 69-90).    
Human rhinoviruses (HRV) are small non-enveloped viruses that belong to the 
family Picoronaviridae (Dreschers et al., 2007, 181-191).  Three distinct species and over 
100 serotypes of HRV have been identified to date (Palmenberg, Rathe and Liggett, 
2010, 1190-9).  Over 90% of HRV species use intercellular adhesion molecule -1 
(ICAM-1) as a cellular receptor to dock to cells of the nasal epithelium and initiate 
infection (Bella and Rossmann, 2000, 291-297).  ICAM-1 exists both on the surface of 
cells and as a soluble protein found in serum and secretions from epithelial tissues.  This 
receptor is expressed by a variety of cell types in response to inflammation and functions 
primarily as an adhesion molecule for leukocytes, allowing neutrophils and other cell 
types to localize to sites of injury or infection.  ICAM-1 expression is increased in nasal 
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epithelial cells in response to HRV infection, representing a potential mechanism for 
enhanced viral replication within infected tissues (Whiteman et al., 2003, 11954-11961).  
This hypothesis is supported by in vitro experiments where anti-ICAM-1 antibodies are 
used to block viral access to the ICAM-1 receptor.  In one example, Whitmann and 
colleagues observed that viral titers recovered from cell culture supernatants decreased in 
a dose-dependent fashion in response to increasing concentrations of anti-ICAM-1 
antibody (2003). 
ICAM-1 is commonly over-expressed in individuals with asthma (Bella and 
Rossmann, 2000, 291-297; Bianco et al., 2000, 339-345; Ciebiada, Gorska-Ciebiada and 
Gorski, 2011, 660-666).  Baseline ICAM-1 expression has been reported to be 3 times 
higher in asthmatic patients compared to healthy controls when measured 
immunohistochemically in cultured nasal epithelium and 4.7 times higher when ICAM-1 
expression was induced in tissue culture incubated with whole blood from asthmatic 
patients (Bianco et al., 2000, 339-345; Horvathova, Jahnova and Gazdik, 2001, 17-30).  It 
has been previously suggested that the elevated levels of ICAM-1 present on the 
respiratory epithelium of individuals with asthma might account for the increased 
incidence of rhinovirus infection in this population (Bianco et al., 2000, 339-345).  
It is widely accepted that vitamin C can reduce the severity and duration of the 
common cold, but the impact of vitamin C on preventing the common cold is less clear 
(Douglas et al., 2007, CD000980).  Vitamin C has antihistamine properties, which likely 
account for some of the observed reduction in symptoms when vitamin C is taken at the 
onset of a cold (Johnston, 1996, 189-213; Subramanian et al., 1973, 1671-1673). 
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Additionally, the antioxidant properties of vitamin C may reduce cold symptoms by 
protecting tissues from oxidative damage that results from virus infection and immune 
response (Uchide and Toyoda, 2011, 2032-2052).  
Interestingly, supplementation with vitamin C has been shown to decrease ICAM-
1 expression in a variety of in vitro and in vivo studies (Jain et al., 2010, 1371-1380; 
Vincent et al., 2009, 254-262; Murphy et al., 2005, 181-190; Scott et al., 2005, 138-144; 
Tahir et al., 2005, 302-306; Son et al., 2004, 1073-1079; Rayment et al., 2003, 339-345).   
There are a number of studies that address HRV infection in individuals with 
asthma (Denlinger et al., 2011, 1007-1014; Ozcan et al., 2011, 888-893; Gavala, Bertics 
and Gern, 2011, 69-90).  Several studies specifically evaluate the relationship of elevated 
ICAM-1 expression to HRV infection in asthmatic subjects (Denlinger et al., 2011, 1007-
1014; Ozcan et al., 2011, 888-893; Gavala, Bertics and Gern, 2011, 69-90).  Separate 
studies have observed a decrease in ICAM-1 levels in response to vitamin C 
supplementation (Jain et al., 2010, 1371-1380; Son et al., 2004, 1073-1079; Rayment et 
al., 2003, 339-345).  One study by Papi and colleagues (2002) identified a dose-
dependent reduction in ICAM-1 expression in response to the antioxidant glutathione in 
HRV-infected respiratory epithelial cells.  To our knowledge, no study has addressed the 
observed reduction in ICAM-1 following supplementation with vitamin C as a potential 
mechanism to reduce risk of rhinovirus infection in asthmatic patients.   
The primary purpose of this study is to evaluate the effect of vitamin C 
supplementation on sICAM-1 concentration in nasal lavage and serum in adult subjects 
with asthma recruited from a university community as part of a preliminary feasibility 
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study.  A secondary aim of this study is to assess participant cold symptoms and serum 
histamine levels during the study period.  We hypothesize that supplementation with 
vitamin C will reduce levels of sICAM-1 both in nasal lavage and serum as well as 
reduce cold symptoms and decrease serum histamine among study participants.  
 
Definition of Terms 
The common cold:  A general term for a mild upper respiratory illness that is 
caused by a number of unrelated viral pathogens.  Symptoms typically include sore 
throat, nasal congestion, cough and fatigue and resolve spontaneously within 3-7 days 
after initiation. 
 
Human rhinovirus (HRV): An icosahedral non-enveloped virus that belongs to the 
Picoronaviridae family of viruses.  The HRV capsid is composed of 4 viral proteins and 
encloses a single-stranded positive-sense RNA viral genome.  HRV is the most frequent 
etiologic agent of the common cold. 
 
Intercellular adhesion molecule-1 (ICAM-1):  Also known as CD54, ICAM-1 is a 
member of a class of cellular adhesion molecules that is expressed by a number of tissue 
types including epithelial tissues and some lymphocytes.  ICAM-1 is a glycoprotein with 
five immunoglobulin domains and consists of extracellular, transmembrane and 
intercellular regions.   
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Soluble Intercellular adhesion molecule-1 (sICAM-1):  sICAM-1 is a soluble 
glycoprotein that is identical to the extracellular region of ICAM-1.  sICAM-1 is thought 
to be derived from epithelial and endothelial tissues by shedding (proteolytic cleavage) of 
the extracellular region of ICAM-1.  However, sICAM-1 may also be derived from 
pathway via alternate splicing of the ICAM-1 gene transcript. 
 
Histamine:  Histamine is an amine derived from the amino acid histidine.  It is an 
important bioactive substance involved in a number of physiological processes. 
Histamine participates in the inflammatory response by stimulating local vasodilation and 
increasing capillary permeability.  Other physiological functions attributed to histamine 
include promoting bronchial smooth muscle constriction and stimulating gastric 
secretions.  In the central nervous system, histamine acts as a neurotransmitter. 
 
Asthma exacerbation:  Commonly known as an asthma attack, asthma 
exacerbation is an acute decrease in peak expiratory volume and lung function related to 
constriction of the bronchioles through local inflammation and smooth muscle 
contraction.  Severe asthma exacerbation can be a medical emergency depending on the 
acuity of symptoms and responsiveness to treatments such as bronchodilators. 
 
Immunohistochemical staining:  A technique for quantifying subcellular 
components on tissue slides using labeled antibodies.  Specific labeled antibodies are 
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used to stain cells and expression of subcellular components is quantified by the intensity 
of the staining.   
 
Delimitations 
The study participants were adults aged 18 to 65 years old who have been 
diagnosed with asthma by a physician and consider themselves to have asthma currently.  
Both men and women were recruited for participation in this study.  Volunteers were 
recruited for study participation from a university community using fliers and e-mail 
distribution lists.   
 
Limitations 
This study has been designed as a preliminary feasibility study to evaluate the 
effect of a vitamin C supplementation protocol on sICAM-1 concentration in nasal lavage 
and plasma of asthmatic study participants.  This study is limited by small sample size.  
Power analysis was not completed because the primary outcome measure, change in 
sICAM-1 concentration in nasal lavage in response to a dietary intervention, has not been 
previously reported in the literature.  Currently there is no clinically useful diagnostic test 
to identify HRV infection; therefore cold symptoms were assessed by self-report 
questionnaire.   
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CHAPTER 2 
REVIEW OF LITERATURE 
The Common Cold 
 Significance and economic impact.  The term “common cold” refers to a group of 
mild and typically self-limiting symptoms that include nasal congestion, sore throat and 
cough that are caused by a viral infection of the upper-respiratory tract (Rollinger and 
Schmidtke, 2011, 42-92).  As one of the most common illnesses, colds account for 
significant morbidity world-wide with a large associated economic impact.  In the United 
States alone, the common cold is estimated to cost $25 billion annually in lost 
productivity and $17 billion in direct medical costs (Bramley, Lerner and Sarnes, 2002, 
822-829; Fendrick et al., 2003, 487-494).  Recent estimates suggest as many as 214 
million lost workday equivalents are a result of the common cold each year, with about 2 
million lost workdays due to caring for sick children (Rollinger and Schmidtke, 2011, 42-
92). 
Current treatment.  There is currently no specific treatment for the common cold 
(Rollinger and Schmidtke, 2011, 42-92).  Typical medical treatment focuses on 
alleviation of symptoms and includes nasal decongestants, analgesics, fluids and rest 
(Rollinger and Schmidtke, 2011, 42-92).  Developing a vaccine against the common cold 
is considered an ineffective strategy because there are many viruses that cause the 
symptoms of the common cold.  Over 200 different viruses can cause the symptoms of 
the common cold while the most important of these viruses has more than 100 antigenic 
types (Bella and Rossmann, 2000, 291-297; Rollinger and Schmidtke, 2011, 42-92; 
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McKinlay, 2001, 477-481).  While the symptoms of the common cold may create misery 
and suffering in affected individuals, a cold poses very little risk of serious illness in most 
people.  Since otherwise healthy individuals with colds experience a mild illness that 
spontaneously resolves in a short period of time, any new therapy developed to treat the 
common cold must have an excellent safety profile to ensure an acceptable risk to benefit 
ratio (McKinlay, 2001, 477-481).  Given the significant challenges of developing a 
vaccine or specific therapy to “cure the common cold,” the low risk of complications for 
generally healthy individuals, and the high standard of safety that must be met, 
development of a new specific treatment for the common cold is unlikely in the near 
future.  
The Human Rhinovirus.  While a number of different viral pathogens can cause 
the symptoms of the common cold, human rhinovirus (HRV) is the most clinically 
important and is responsible for 50% to 80% of colds (Poland and Barry, 2009, 2245-
2246).  HRVs are small non-enveloped viruses consisting of a single, positive sense 
strand of RNA within an icosahedral capsid (Dreschers et al., 2007, 181-191).  As a 
member of the Picoronaviridae family of viruses, HRV is a diverse group that includes 
three distinct species and over 100 identified serotypes (Palmenberg, Rathe and Liggett, 
2010, 1190-9).   Despite this variety, most HRVs use the same receptor to gain access to 
target cells, intercellular adhesion molecule-1 (ICAM-1).  Within the HRV-A and HRV-
B species, there are at least 88 virus isoforms that use ICAM-1 as a receptor.  When a 
viral particle binds to ICAM-1, it is taken into the cell by endocytosis.  The mechanistic 
details of how the viral RNA molecule leaves the resulting endosome to begin the process 
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of viral replication are not completely resolved.  A current theory proposes a process that 
is mediated by the interaction of the viral capsid proteins with ICAM-1 in the low pH 
conditions of late endosomes (Fuchs and Blaas, 2010, 281-297).   
The remaining 11 viruses within the HRV-A species bind to the very low density 
lipoprotein (VLDL) receptor.  HRV-C is the third and most recently identified species.  
At least 11 viruses belong to this species, but a receptor has not been identified for this 
group (Palmenberg, Rathe and Liggett, 2010).  HRV-C does not replicate in commonly 
used cell culture lines and has been grown with only limited success in sinus tissue 
culture, potentially accounting for its recent discovery.  Both genetic sequence 
comparisons and in vitro studies of HRV-C using anti-ICAM-1 and anti-VLDL 
antibodies and support the conclusion that HRV-C has a distinct receptor specificity from 
other HRV species (Bochkov and Gern, 2012, 485-494).  Despite its recent 
characterization, HRV-C is both genetically diverse and prevalent within groups that 
have been sampled, suggesting that it is not a newly emergent group, but that it has been 
present in the human population for some time (Lee et al., 2012, 886-891; Mackay et al. 
2012). 
Seasonality and severity.  While HRV infection occurs throughout the year, the 
rate of infection follows a seasonal pattern, with the highest rate occurring in the fall and 
spring (Brownlee and Turner, 2008, 67-71).  Lee and colleagues (2012) used a 
prospective cohort design to characterize factors that affect severity of illness from HRV 
infection among children enrolled in the childhood origins of asthma (COAST) study at 
birth.  Enrollment criteria for this study included one or more parents with a history of 
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allergic sensitization such as asthma or positive skin test and birth at 37 weeks gestation 
or greater.  A total of 285 infants were followed for 12 months.  Study measures included 
nasal lavage samples taken during scheduled study visits at 2, 4, 6, 9, and 12 months of 
age, irrespective of whether the child was showing signs of illness.  Additional nasal 
lavage samples were collected either by parents or clinic staff each time a child had 
symptoms of a respiratory illness.  Severity of illness was classified according to a 
respiratory symptom scorecard.  All nasal lavage samples were screened for 20 common 
respiratory viruses and samples that tested positive for HRV were further analyzed and 
typed using serological and genetic techniques (Lee et al., 2012, 886-891).   
Lee and colleagues’ (2012) findings confirmed prior characterizations of the 
seasonality of HRV infection and demonstrated relationships between HRV type and 
severity of respiratory illness in infants during the first year of life.  Most infants in this 
cohort, 72.3%, had at least one nasal lavage sample positive for HRV infection during the 
first 12 months of life with the rate of infection three times higher in Fall (September, 
October) and Spring (March) compared to other seasons.  The authors demonstrated a 
relationship between severity of illness and month of infection, finding that more 
moderate to severe illnesses occurred with HRV infection in the months of December to 
February compared with the months of April to August.  Severity of illness was strongly 
related to HRV virus type.  Both HRV-A and HRV-C infections were seven times more 
likely to be associated moderate to severe illness than HRV-B (Lee et al., 2012, 886-891).  
In a similar prospective cohort study, Mackay and colleagues (2012) enrolled 234 
healthy children five years of age or younger and followed them for a year to characterize 
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the diversity and clinical impact of HRV species circulating in preschool-aged children.  
Nasal swabs were collected by parents from participants who showed symptoms of viral 
upper respiratory infection.  Specimens were evaluated for the presence of HRV and 
other common respiratory viruses using conventional and reverse transcription 
polymerase chain reaction methods.  All HRV-positive samples were further 
characterized using genetic techniques.  A seasonal pattern of illness was observed, 
similar to the findings of other studies, with peaks in spring and fall.  However, no 
association between virus species and clinical outcomes was identified (Mackay et al., 
2012).   
In this investigation, Mackay and colleagues (2012) did not report a score of 
subjective illness severity but measured incidence of co-occurring fever, otitis media or 
wheeze.  There was a low incidence of wheeze reported in this study with 6 cases of 
virus-associated wheeze out of 563 episodes of acute upper respiratory illness.  The 
authors speculate that the low rate of wheeze in this cohort was related to exclusion 
criteria of history of asthma or prior wheeze.  One of the significant findings of this study 
is the diversity of HRV species circulating in the study population over the course of one 
year.  A total of 74 different HRV species were identified within the study cohort.  
Repeated HRV infection was common, with a mean rate of 1.8 HRV infections per child.  
While no study participants were infected with the same virus type twice in the study 
period, the same virus species may have been detected more than once in different cold 
episodes.  HRV-A and HRV-C were the most common species accounting for 41.5% and 
47.5% of genotyped samples, respectively (Mackay et al., 2012).  
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A notable difference between the two studies by Lee and MacKay is that asthma 
diagnosis or history of wheeze were used as exclusion criteria by MacKay’s group, 
whereas Lee and colleagues enrolled infants with increased risk for developing asthma 
based on parents’ medical history.  The two groups also differed in measures of the 
impact of HRV infection in study participants.  Lee’s group used a subjective assessment 
of illness severity based on symptoms while MacKay and colleagues used clinical 
outcome measures such as fever or ear ache to assess illness severity.  Fever and ear ache 
are frequent complaints within a preschool age group, but not classical symptoms of the 
common cold (i.e., nasal congestion, runny nose, cough, etc.).  
Pathogenesis.  HRV infection is spread by contact.  Viral particles are transferred 
by the hands from a contaminated surface to the nose or eyes.  If HRV is transferred to 
the eyes, the virus reaches the nasal epithelium through the lacrimal duct (Kirchberger, 
Majdic and Stockl, 2007, 1-10).  Once introduced into the nose, viral particles are swept 
to the adenoid at the back of the nasopharynx through the action of ciliated epithelium.  
HRV then binds to specific receptors to enter cells and initiate infection (Rollinger and 
Schmidtke, 2011, 42-92; Kirchberger, Majdic and Stockl, 2007, 1-10).  The primary site 
of infection is the ciliated epithelial tissue of the nasopharynx, although HRV infection 
has also been detected non-ciliated epithelium and in the lower respiratory tract 
(Rollinger and Schmidtke, 2011, 42-92; Kirchberger, Majdic and Stockl, 2007, 1-10).  
The incubation period following exposure before cold symptoms emerge is short, lasing 
only 10-12 hours (Rollinger and Schmidtke, 2011, 42-92).   Viral shedding peaks two to 
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three days following initial infection and declines immediately following the peak 
(Dreschers et al., 2007, 181-191). 
The symptoms of a cold are thought to result from an inflammatory process 
initiated by infected host epithelial cells and not from tissue damage caused by HRV 
infection.  This theory of HRV pathogenesis has emerged from a number of observations 
at the tissue and cellular level.  Interestingly, HRV replicates in only 10% of the cells in 
an infected tissue (Kirchberger, Majdic and Stockl, 2007, 1-10).  This rate of infection 
seems insignificant compared to the severity of symptoms experienced by many cold 
sufferers.  Also, nasal biopsy specimens from individuals infected with HRV are typically 
negative for the histopathological changes that are consistent with significant tissue 
damage (Dreschers et al., 2007, 181-191).  Nasal secretions from HRV infected 
individuals contain a number of inflammatory cytokines including IL-6 and IL-8.  These 
cytokines are powerful chemoattractant signals that promote the infiltration of neutrophils 
and other leukocytes to the site of infection and further exacerbate local inflammation 
(Kirchberger, Majdic and Stockl, 2007, 1-10).  
Immune system interactions.  Some estimates suggest that a typical U.S. adult 
experiences 2.5 colds per year on average (Fendrick et al., 2003, 487-494).  Given the 
high prevalence of HRV, more than half of these upper respiratory illnesses are likely a 
result of HRV infection (Poland and Barry, 2009, 2245-2246).  In a study where 
volunteers were experimentally infected with a strain of HRV-A, Barclay and colleagues 
(1989) observed a specific antibody response in serum and nasal secretions 1-2 weeks 
after inoculation which remained in most participants for a year or longer.  This response 
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did not confer lasting protection from HRV re-infection in all participants as 2 out of 14 
subjects were re-infected when challenged with the same strain one year after the initial 
infection.  However, the volunteers appeared to have reduced the severity of illness in 
subsequent infections (Barclay et al., 1989, 659-669).  Other investigators have shown 
that multiple infections by different strains of virus in the same HRV species during a 
single year is not uncommon (Mackay et al., 2012). 
The high diversity among HRVs (> 100 serotypes) is one factor that accounts for 
weak immune protection.  A recent investigation by Niespodziana and colleagues (2012) 
revealed an additional immune evasion property of HRV.  The authors evaluated the 
antibody response to each of the 4 HRV capsid proteins, designated VP1-VP4, in the 
blood of children with confirmed HRV infection.  Subjects in this investigation were 56 
children with naturally acquired upper respiratory illness recruited from physician 
offices.  HRV infection was confirmed by polymerase chain reaction in 48 of the 56 
enrolled study participants.  Serum samples were evaluated for antibody response to each 
of the viral proteins (Niespodziana et al., 2012, 1001-1008).   
While the subjects produced some antibodies to each of the 4 viral proteins, the 
strongest antibody response was directed against VP1, the viral capsid protein that 
interacts with the ICAM-1 receptor.  The investigators mapped the epitope specificity of 
the anti-VP1 antibodies in the sera of study participants and found the strongest response 
was to a 20-amino acid fragment at the n-terminus of the VP1 protein.  In the complete 
viral capsid, this portion of VP1 is not exposed except during un-coating when VP1 is 
bound to ICAM-1.  The major finding of this study is that most of the anti-HRV 
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antibodies produced by the participants were not capable of neutralizing HRV particles.  
This observation lead the authors to conclude one reason for recurrent HRV infection is a 
misdirected antibody response (Niespodziana et al., 2012, 1001-1008).  
An in vitro model of HRV pathogenesis has been developed by Hosoda and 
colleagues (2002) to explore some facets of the effect of HRV on inflammatory signaling 
by immune cells.  Their findings indicate HRV infection primes mast cell and basophil 
cell lines to produce significantly more histamine, interleukin-4 (IL-4), interleukin-6 (IL-
6) and interleukin-8 (IL-8) when stimulated with phorbol myristate acetate (PMA) than 
uninfected controls (Hosoda et al., 2002, 1482-1491).  PMA is a compound commonly 
used in cell biology experiments to stimulate cytokine production in cytokine-secreting 
cells.  The actions of histamine are associated with many common cold symptoms such 
as nasal congestion or runny nose (DeFranco, Locksley and Robertson, 2007, 302-317).  
Individual cytokines have many functions and act on multiple cell types in a coordinated 
and redundant fashion.  Many of the principal effects of IL-4, IL-6, and IL-8 are closely 
related to the symptoms and pathophysiology of HRV infection.  IL-4 stimulates 
differentiation of helper T cells and also plays a role in allergy and asthma.  IL-6 is a pro-
inflammatory cytokine that recruits monocytes to an area of inflammation.  IL-8 recruits 
granulocytes including neutrophils to the site of inflammation and promotes histamine 
release in surrounding tissues (DeFranco, Locksley and Robertson, 2007, 302-317).  
Hosoda and colleagues’ (2002) model of HRV infection is different from a natural HRV 
infection in that cultured mast cell and basophil cell lines were modified in order to be 
infected with the HRV virus.  Physiological HRV infection occurs in nasal epithelial 
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cells, not leukocytes.  This experimental model is not a true-to-life representation of in 
vivo HRV infection.  However, it is suggestive with respect to the ability of HRV to 
promote modulation of inflammatory response. 
HRV modulates the expression of host genes related to immune function.  
Whiteman and colleagues (2003) evaluated the effect of HRV infection in cultured 
human bronchial epithelial cells on the production of both soluble ICAM-1 (sICAM-1) 
and membrane bound ICAM-1.  Unique mRNA transcripts were observed for each of the 
ICAM-1 proteins.  HRV infection induced an increase in ICAM-1 protein expression at 
the cell surface 2.5 times greater than the basal rate and an increase in ICAM-1 mRNA 
expression 2 times greater than the basal rate.  The amount of sICAM-1 recovered from 
culture supernatants varied in a time-dependent manner in control cultures.  However, no 
sICAM-1 protein was recovered from culture supernatants in HRV infected cell cultures.  
The rate of sICAM-1 mRNA expression was reduced to half of the basal rate in HRV 
infected cell cultures (Whiteman et al., 2003, 11954-11961).   
 
Intercellular Adhesion Molecule-1 
Overview.  ICAM-1, also known as CD54, is a member of the immunoglobulin 
superfamily that is expressed on the surface of many cell types, ranging from 
lymphocytes such as tissue monocytes and dendritic cells to surface tissues like vascular 
endothelium and mucosal epithelium (Long, 2011, 5021-5023). In endothelium, ICAM-1 
functions to provide an adhesion site for lymphocytes in the blood steam, allowing 
lymphocytes to migrate from the blood to a site of inflammation.  Similarly, ICAM-1 
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expression on the surface of epithelial cells allows lymphocytes to localize to a site of 
inflammation and enter affected tissues through diapedesis (Bella and Rossmann, 2000, 
291-297).   
Structure and Ligands.  The structure of ICAM-1 consists of cytoplasmic, 
transmembrane and extracellular regions (Witkowska and Borawska, 2004, 91-98).  The 
cytoplasmic region of ICAM-1 is anchored to the actin cytoskeleton and this connection 
to the cytoskeleton is necessary for ICAM-1 to stimulate some components of the 
immune system (Long, 2011, 5021-5023).  The extracellular region is heavily 
glycosylated and consists of five immunoglobulin (Ig) domains (Bella and Rossmann, 
2000, 291-297).  Immune cells recognize and bind to distinct ICAM-1 Ig domains 
through two different β-integrin receptors: leukocyte function-associated antigen (LFA-1) 
and macrophage-1 antigen (Mac-1) (Bella and Rossmann, 2000, 291-297).  ICAM-1 can 
exist on the cell surface either as a monomer or as a dimer.  The dimerized form of 
ICAM-1 exhibits the highest binding affinity for LFA-1 (Witkowska and Borawska, 
2004, 91-98).   
A soluble form of ICAM-1 (sICAM-1) circulates in the blood and can be detected 
in a number of different body fluids and secretions.  sICAM-1 is similar to ICAM-1, 
except that it lacks the transmembrane and intercellular domains of membrane-bound 
ICAM-1 (Witkowska and Borawska, 2004, 91-98).  Two mechanisms for sICAM-1 
production have been identified.  Champagne and colleagues (1998) described a 
mechanism of proteolytic cleavage of ICAM-1 at the membrane surface mediated by 
human neutrophil elastase.  This mechanism represents the shedding of ICAM-1 from the 
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cell surface and agrees with the observation that sICAM-1 concentration in culture 
supernatants is related to the amount of ICAM-1 expression on the cell surface 
(Witkowska and Borawska, 2004, 91-98).  Distinct mRNA transcripts coding for both 
forms of ICAM-1 have been observed in cell culture.  Whiteman and colleagues (2003) 
identified unique mRNA transcripts for ICAM-1 and sICAM-1 and showed that gene 
expression can be independently regulated for each protein.  
ICAM-1 is exploited as a receptor by three different pathogens.  Plasmodium 
falciparum, the parasite that causes malaria, directs infected blood cells to adhere to the 
endothelial surface of deep capillary beds using ICAM-1.  Binding of infected red blood 
cells to capillary walls may be a method of immune evasion, but it also contributes to the 
virulence of the malarial parasite by creating blockages in blood vessels (Bella and 
Rossmann, 2000, 291-297).  Some members of the Coxsackievirus A genus as well as the 
major subgroup of HRVs use ICAM-1 as a receptor to gain entry into epithelial cells.  
Coxsackievirus A, like HRV, belongs to the Picoronaviridae family and Enterovirus 
genus.  Various Coxsackie A virus species cause illnesses including the common cold, 
hand, foot and mouth disease, and viral meningitis (Rossmann et al., 2000, 239-247).  A 
number of virus species within this genus require the interaction of other factors and 
receptors in addition to ICAM-1 to initiate infection (Newcombe et al., 2003, 3041-
3050). 
Although there are some variations in the precise mechanisms, i.e. additional co-
factors or co-receptors, both viruses are thought to bind to ICAM-1 in a similar way 
described as the canyon hypothesis.  The three-dimensional structure of the viral capsids 
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are very similar and have a small depression, or canyon, at the icosahedral vertices which 
receives the portion of ICAM-1 that is most distal from the cell membrane (Rossmann et 
al., 2000, 239-247).  
Factors effecting ICAM-1 Expression.  ICAM-1 may be constitutively expressed 
at a low rate in some tissues, but increases dramatically during infection or injury (Fuchs 
and Blaas, 2010, 281-297).  Mast cells and macrophages produce inflammatory cytokines 
at the site of damage including interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α).  
Tissue cells rapidly translocate ICAM-1 to the cell surface when exposed to TNF-α or IL-
1, acting as a target for recruitment of additional lymphocytes (DeFranco, Locksley and 
Robertson, 2007, 22-53).  sICAM-1 levels increase in a number of disease states, 
particularly in conditions involving inflammation such as rheumatoid arthritis, 
atherosclerosis, and hypertension (Witkowska and Borawska, 2004, 91-98).  Increased 
ICAM-1 expression has been detected in the respiratory epithelium of patients with 
atopic (allergy-induced) asthma (Bianco et al., 2000, 339-345).   
Drugs with anti-inflammatory properties decrease ICAM-1 expression.  Valera 
and colleagues (2011) used tissues cultured from nasal polyp biopsy specimens to assess 
the effect of the corticosteroid drug fluticasone propionate on markers of inflammation, 
including ICAM-1.  Tissue from nasal polyp biopsies was selected as a model system 
because nasal polyps form as part of a severe chronic inflammation of the upper 
respiratory tract and are often treated with corticosteroid nasal sprays.  Nasal polyp 
tissues express ICAM-1 at a high rate constitutively.  Fluticasone propionate decreased 
ICAM-1 gene expression and sICAM-1 protein level in a dose dependent manner (Valera 
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et al., 2011, 605-610).  A similar study by Sabatini and colleagues (2003) assessed the 
effect of two different corticosteroid drugs on markers of inflammation in a cell culture 
model of lung tissue.  In this study, human fetal lung fibroblast cells were exposed to 
TNF-α to stimulate production of inflammation-related proteins.  The authors compared 
relative effects of mometasone furoate and dexamethasone on inflammatory markers.  A 
dose-dependent decrease in ICAM-1 was seen with both drugs in the TNF-α stimulated 
cell cultures.  Treatment at the highest concentration of mometasone furoate had a 
powerful effect, lowering ICAM-1 expression below the constitutive level of ICAM-1 
expression in unstimulated cells (Sabatini et al., 2003, 287-297). 
Human rhinovirus.  During HRV infection, the expression of ICAM-1 increases 
significantly in nasal epithelium within the first 24 hours after infection in both in vitro 
and in vivo.  In vitro experiments have shown a complete suppression of sICAM-1 
release in culture supernatants from HRV infected cells (Whiteman et al., 2003, 11954-
11961).  In experimentally induced HRV infection in human volunteers, the level of 
sICAM-1 detected in nasal secretions has been observed to increase slightly, but appears 
to lag behind the increase in membrane-bound ICAM-1 and increase to a lesser extent 
(Winther et al., 2002, 131-136).  The increase in ICAM-1 expression that occurs in 
response to HRV infection represents a mechanism that favors increased viral replication 
and spread of viral infection within a tissue.  In contrast to ICAM-1, sICAM-1 has anti-
viral properties and suppresses HRV replication (Witkowska and Borawska, 2004, 91-
98).  Viral particles that are docked to sICAM-1 have fewer binding sites available to 
attach to ICAM-1 at the cell surface and may be less able to cause infection.  HRV is able 
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to modulate the expression of ICAM-1 within nasal epithelial cells in a way that 
promotes viral replication.  Observations in cultured bronchial epithelial cells indicate 
that HRV is able to alter the levels ICAM-1 messenger RNA to increase the expression of 
membrane-bound ICAM-1 and decrease the release of sICAM-1 (Papi and Johnston, 
1999, 9707-9720; Whiteman et al., 2003, 11954-11961).  These changes may promote 
increased viral replication through increased binding to ICAM-1 and decreased host 
defenses through suppression of sICAM-1. 
Dietary factors that influence ICAM-1 expression.  Dietary factors modulate the 
expression of both sICAM-1 and ICAM-1.  Cell culture models of ICAM-1 expression 
have shown a reduction in ICAM-1 in response to various dietary antioxidants in stressed 
cells.  In one such experiment, Mo and colleagues (2003) used cultured endothelial cells 
in an investigation of phytochemicals and inflammation.  Human umbilical endothelial 
cells were first stimulated with TNF-α to produce ICAM-1.  The effect of alginate 
(present in seaweed), allicin (present in garlic) and vitamin C on TFN-α stimulated 
cultures was assessed by ELISA.  The investigators measured a significant and dose-
dependent decrease in TFN-α stimulated ICAM-1 production in response to all three 
compounds, with the greatest percent inhibition achieved by vitamin C.  Addition of 
these three compounds to unstimulated cells did not significantly alter the baseline 
ICAM-1 expression (Mo et al., 2003, 244-251). 
The influence of dietary factors on ICAM-1 has been investigated in a number of 
human trials involving supplements and dietary interventions.  In a randomized, double-
blind, crossover study, Rayment and colleagues (2003) investigated the effect of vitamin 
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C supplementation on monocyte ICAM-1 expression in healthy adults.  The investigators 
recruited apparently healthy men between the ages of 20 and 45 who were non-smokers, 
had no history of heart disease and were not currently taking supplements.  Study 
participants were supplemented with 250 mg of vitamin C daily for six weeks.  Monocyte 
ICAM-1 protein expression was measured using flow cytometry while ICAM-1 gene 
expression was measured by PCR.  Plasma sICAM-1 level was measured using ELISA 
(Rayment et al., 2003, 339-345).  For analysis, study participants were grouped by 
baseline vitamin C status into a low vitamin C group (LOC) with plasma levels < 50 µM 
and an above average vitamin C group (HIC) with plasma levels ≥ 50 µM.  Both groups 
demonstrated an increase in plasma vitamin C after 6 weeks of supplementation, but the 
LOC group demonstrated the greatest increase with plasma vitamin C levels 2-fold 
greater than baseline.  The LOC group showed the greatest decrease in ICAM-1 gene 
expression and had significantly lower plasma sICAM levels.  Monocyte ICAM-1 levels 
were not significantly reduced in either group following supplementation.  The HIC 
group did not show a significant decrease in ICAM-1 gene expression in response to 
vitamin C supplementation (Rayment et al., 2003, 339-345). 
Because of its role in inflammation, ICAM-1 has been investigated in relation to 
diseases that have an inflammatory component, such as atherosclerosis and heart disease.  
Several studies have explored the effect of antioxidant nutrients on ICAM-1 as an 
intervention in inflammatory disease states.  In one investigation of exercise-induced 
endothelial dysfunction in patients with intermittent claudication, intravenous vitamin C 
infusion (50 mg/minute for 20 minutes) reduced an exercise-induced increase in plasma 
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sICAM-1 (Silvestro et al., 2002, 277-283).  In another study with subjects at high risk for 
cardiovascular disease, investigators developed a dietary intervention involving walnut-
enriched meat products (Canales et al., 2011, 703-710).  The rational for using walnuts as 
part of a dietary intervention related to prior findings that walnut-enriched meat products 
improved the antioxidant status of study participants at high risk for heart disease.  The 
findings from this study showed a significant decrease in plasma sICAM-1 following the 
5-week intervention, highlighting the effect of antioxidant-rich whole foods on plasma 
sICAM-1 (Canales et al., 2011, 703-710).  
 
Vitamin C Overview 
 Antioxidant function.  Vitamin C (ascorbic acid) is the most significant aqueous 
antioxidant in human serum.  Ascorbic acid carries out its antioxidant function by 
donating a hydrogen atom to an oxidizing species and interrupting the chain of oxidative 
reactions.  In this process, ascorbic acid is converted first to an intermediate ascorbate 
free radical which is then converted to dehydroascorbate.  Dehydroascorbate can be 
recycled back to ascorbic acid or may form 2,3-diketo-l-gluconic acid which cannot be 
recycled to ascorbic acid and is excreted after further degradation (Asard, May, and 
Smirnoff, 2004, 139-152).  In serum, vitamin C travels freely as ascorbic acid and 
oxidized dehydroascorbate is taken up by red blood cells via GLUT glucose transporters 
for recycling (Combs, 2012, 233-261).     
Enzymatic co-factor functions.  Vitamin C is also an essential co-factor for the 
function of a number of enzymes that are dependent on reduced copper or iron for their 
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catalytic function, i.e. Cu+-dependent monooxygenases and Fe2+-dependent dioxygenases 
(Linster and Van Schaftingen, 2007, 1-22).  Physiological functions such as collagen 
synthesis, tyrosine metabolism, carnitine synthesis and epinephrine/norepinephrine 
synthesis all depend on vitamin C for the function of at least one enzyme in their 
respective metabolic pathways.  Scurvy is the disease that results from vitamin C 
deficiency and has various symptoms that can be attributed to dysfunction of these 
enzymatic pathways (Asard, May, and Smirnoff, 2004, 159-169).  Some of the most 
readily apparent symptoms of scurvy result from defects in collagen synthesis and 
include swollen, bleeding gums, tooth loss, bruising, hemorrhage, bone malformation and 
joint pain.  Individuals affected by scurvy also exhibit fatigue, weakness, apathy and 
malaise which are thought to result from defects in the synthesis of the neurotransmitters 
epinephrine and norepinephrine as well as defects in carnitine synthesis which is 
necessary for the oxidation of fatty acids for energy.   
Dietary Reference Intake.  The current dietary reference intake for vitamin C 
established by the Institute of Medicine’s Food and Nutrition Board (2000) recommend 
an intake of 75 mg per day for adult women and 90 mg per day for adult men.  This 
recommendation is based on maximizing vitamin C concentration in neutrophils and 
minimizing urinary ascorbic acid excretion.  The tolerable upper limit is set to 2,000 mg 
daily based on minimizing gastrointestinal distress and osmotic diarrhea that can occur 
with ingestion of high supplemental doses (> 3,000 mg) of vitamin C although high 
supplemental doses of vitamin C from 2,000-4,000 mg per day are considered relatively 
non-toxic (Food and Nutrition Board, Institute of Medicine, 2000; Johnston, 1999, 71-
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77).  Doses of vitamin C that optimize physiologic function in vivo may be considerably 
higher than DRI levels.  For example, when Heinz bodies and lipid peroxidation were 
used as measures of oxidative stress in plasma, supplemental doses of vitamin C between 
500 and 1000 mg daily provided maximal protection in healthy adults.  Higher doses of 
vitamin C at the level of 2000 mg daily maintained the level of benefit achieved at the 
500-1000 mg level, but did not confer additional benefit (Johnston and Cox, 2001, 623).  
 Vitamin C Status in the United States.  Several factors including age, sex, 
smoking and socioeconomic status were associated with serum vitamin C concentration 
in a nationally representative sample of the United States population.  Overall, the 
prevalence of vitamin C deficiency in the 2003-2004 National Health and Nutrition 
Examination Survey (NHANES) was 7.1% (Schleicher et al., 2009, 1252-1263).  The 
demographic groups with the lowest mean serum vitamin C concentration were smokers, 
men between 20 to 59 years of age and individuals with low income.  Population sub-
groups with the highest mean serum vitamin C concentration included children between 6 
and 11 years old and adolescents between 12 and 19 years old and females 12 years of 
age and older (Schleicher et al., 2009, 1252-1263). 
 Historical Controversies in Vitamin C Research.  In 1970, respected scientist and 
two-time Nobel Laureate Linus Pauling published his book Vitamin C and the Common 
Cold.  Pauling advocated supplemental doses of vitamin C in amounts ranging from 1 to 
10 grams daily and asserted that high-dose supplemental vitamin C could extend an 
individual’s life by between 2 and 6 years.  This publication was not well accepted by the 
scientific community, generating considerable criticism (Bing, 1971, 1506-1506; Hodges, 
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1971, 532).  Following the publication of Vitamin C and the Common Cold, several 
studies were undertaken to assess whether Pauling’s claims had scientific merit 
(Anderson, 1975, 498-504; Karlowski et al., 1975, 1038-1042).  However, the 
controversy surrounding Pauling’s dramatic claims with respect to vitamin C was so 
significant that it may have impacted contemporary researchers’ interpretations of 
vitamin C supplementation trials.  For example, Karlowski and colleagues (1975) 
conducted a randomized, placebo-controlled trial of the effect of vitamin C 
supplementation on common cold symptoms among National Institutes of Health 
employees in 1975.  In this trial, the authors observed no significant reduction in the 
frequency of colds, but there was a dose-dependent reduction in the duration and severity 
of cold symptoms, which the authors attributed to the placebo effect (Karlowski et al., 
1975, 1038-1042).  Later authors who reviewed the Karlowski trial have argued that 
attributing the observed dose-dependent reduction in the duration of colds to a placebo 
effect was not consistent with the study findings (Hemilä, 1996, 1079-1084). 
Vitamin C and the Common Cold.  Currently, there is general agreement that 
vitamin C can decrease the severity and duration of the common cold, but the evidence is 
less clear with respect to prevention.  For example, when writing for the Cochrane 
Collaboration, Hemilä and colleagues (2010) concluded that prophylactic vitamin C 
supplementation did not reduce the frequency of colds but did reduce duration and 
severity of colds.  However, a number of individual trials have shown a preventative 
effect of vitamin C for the common cold in healthy volunteers (Van Straten and Josling, 
2002, 151-159; Sasazuki et al., 2006, 9-17).  Since “the common cold” is a general term 
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that describes an illness that can be caused by a number of unrelated pathogens, some of 
these observed differences in effect may be related to differences in the cause of cold 
symptoms.  Also, different subject populations tend to show different effects of vitamin C 
on cold prevention.  For example, studies in participants who are subject to high levels of 
stress show a preventative effect of vitamin C against cold incidence.  In one such study, 
Peters and colleagues (1993) compared ultra-marathon (>42 km) runners to age-matched 
non-running controls in a double-blind placebo-controlled trial.  Both groups were 
supplemented with 600 mg vitamin C daily for 21 days prior to an ultra-marathon race 
and then assessed for cold symptoms during the 14-day period following the race.  In this 
sample, 68% of runners receiving placebo reported cold symptoms following the race 
compared to 33% in the supplement group (p <0.01).  Runners in the supplement group 
and matched controls who reported cold symptoms also experienced a shorter duration of 
colds compared to placebo control (Peters et al., 1993, 170).   
 
Asthma Overview 
 Prevalence and impact.  The most recent report from the US Centers for Disease 
Control found that the overall prevalence of asthma in the US population had increased 
by 12.3% between 2001 and 2009, bringing the most current estimates of asthma 
prevalence in the US to 8.2% (Zahran et al., 2011, 547).  This prevalence rate represents 
about 24.6 million people affected in 2009.  The authors found that some demographic 
groups bear a disproportionate burden of asthma compared to the general population.  
This study found that the prevalence of asthma was significantly greater for children than 
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adults.  Among children, boys (11.3%) and non-hispanic blacks (17%) had the highest 
prevalence.  Asthma prevalence was greater among individuals with household incomes 
below the federal poverty level with an overall prevalence of 11.6%.  Children in poor 
households had an asthma prevalence of 13.5% (Zahran et al., 2011, 547).  Given the 
high prevalence of asthma, findings of significant cost to society from this disease are not 
surprising.  Using data from the Medical Expenditure Panel Survey 2002-2007, Barnet 
and Nurmagambetov (2011) estimated the incremental cost of asthma at $56 billion.  The 
authors attributed $3.8 billion to lost productivity from asthma morbidity and $2.1 
million to mortality related to asthma in 2009 dollars (Barnett and Nurmagambetov, 
2011, 145-152). 
Pathophysiology.  Asthma is a chronic disorder characterized by airway 
hyperreactivity, reversible airway obstruction and specific histopathological changes 
resulting from inflammatory airway remodeling (Maddox and Schwartz, 2002, 477-498).  
Hyperreactivity refers to the inflammatory response of the airway to environmental 
factors such as pet dander or pollen that do not produce a response in healthy individuals.  
Symptoms can vary, but typically include cough, wheeze and shortness of breath.  While 
there are various etiologies of asthma, atopic or allergy-induced asthma is one of the best 
characterized manifestations of asthma.  Immunologically, atopic asthma results from a 
dysregulated T helper 2 cell response (Jacobsen et al., 2007, 18-26).  The normal function 
of T helper 2 cells is to coordinate epithelial barrier immunity against invading arthropod 
and helminth pathogens (DeFranco, Locksley and Robertson, 2007, 274-277).  T helper 2 
cells orchestrate the responses of B cells, eosinophils, basophils, mast cells and 
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macrophages as well as epithelium and smooth muscle in a coordinated response to 
hinder the ability of blood-sucking worms or biting insects to feed.  In response to a 
specific antigen, stimulated T helper 2 cells secrete IL-4, IL-13, IL-5 and IL-9, each of 
which has a specific effect in stimulating a barrier immunity response.  IL-4 and IL-13 
activate macrophages and B cells, stimulating the B cells to differentiate in to IgE 
secreting plasma cells.  IL-4 and IL-13 act on epithelial tissues to increase mucin 
production and on smooth muscle to increase contractility.  IL-9 is responsible for 
attracting basophils and mast cells and enhancing their survival while IL-5 promotes 
recruitment and enhances survival of eosinophils (DeFranco, Locksley and Robertson, 
2007, 22-53).  
The smooth muscle contraction and localized edema of a well-controlled T helper 
2 cell response is effective in dislodging worms and impairing the ability of biting insects 
to feed.  However, in atopic asthma T helper 2 cells initiate an inflammatory response to 
benign allergens in the airway that results in vascular edema and smooth muscle 
contraction within the bronchioles, leading to a restricted airway.  T helper 2 cells release 
inflammatory cytokines and chemokines which in turn increase expression of adhesion 
molecules in the local vascular endothelium drawing lymphocytes of hematopoietic 
origin such as neutrophils, mast cells and eosinophils (Maddox and Schwartz, 2002, 477-
498). 
The T helper 2 response generates a powerful chemoattractant stimulus for 
eosinophils.  Eosinophils are one of the primary leucocytes associated with asthma 
symptoms.  Eosinophil counts in bronchial lavage and eosinophil granule proteins have 
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been correlated with severity of asthma symptoms and eosinophils are the primary 
cellular infiltrate found in the lung tissue of asthma patients (Maddox and Schwartz, 
2002, 477-498).  Eosinophils enter the lung parenchyma by an integrin-mediated process 
which involves cell rolling or loose adhesion via P- or E-selectin, followed by firm 
adhesion between integrin and ICAM-1.  After firm adhesion to the vascular 
endothelium, eosinophils leave the circulation through extravasation or diapedesis and 
migrate into the lung tissue (DeFranco, Locksley and Robertson, 2007, 118-151).  
Histological examination of asthmatic lung tissue reveals eosinophils localize 
immediately below the respiratory epithelium and above the smooth muscle layer 
(Maddox and Schwartz, 2002, 477-498).   
Asthma and Diet.  Various studies have related dietary factors to asthma in both 
adults and children.  Dietary antioxidants including vitamin C, vitamin E, beta carotene 
and selenium have been related to asthma incidence and pulmonary function.  Hu and 
Cassano (2000) used both dietary and serum markers of antioxidant status when assessing 
pulmonary function in an NHANES II data set.  Spirometry measurements following the 
American Thoracic Society standards were collected as part of the NHANES medical 
exam.  The authors used forced expiratory volume as their primary assessment of 
pulmonary function.  Forced expiratory volume measures the maximum volume of air 
that can be exhaled by a subject under forced conditions.  This measure is not specific to 
asthma since any condition that impacts lung function such as chronic obstructive 
pulmonary disease or cystic fibrosis also affects spirometry measurements.  Additionally, 
asthmatics may have normal spirometry values when they are not experiencing an acute 
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exacerbation.  Using multiple linear regression analysis, Hu and Cassano observed a 
positive association between pulmonary function and intake of vitamin C, vitamin E and 
beta carotene after controlling for total calories.  Higher serum levels of these 
antioxidants were also associated with improvements in lung function (Hu and Cassano, 
2000, 975-981).  
A systematic review and meta-analysis of 40 studies relating dietary intake and 
serum vitamin A, C and E to asthma outcome measures concluded that vitamin A and 
vitamin C status was significantly lower in individuals with asthma (Allen, Britton and 
Leonardi-Bee, 2009, 610).  The findings of this meta-analysis indicated that vitamin A 
intake was significantly lower in subjects with asthma compared to non-asthmatic 
individuals.  Interestingly, subjects with severe asthma had lower vitamin A intake that 
subjects with mild asthma.  With respect to vitamin C, dietary intakes and serum status in 
the lowest quartiles was associated with greater risk of asthma.  The authors also found 
that vitamin E was not related to asthma in general, except that subjects with severe 
asthma had significantly lower intakes of vitamin E than subjects with mild asthma 
(Allen, Britton and Leonardi-Bee, 2009, 610).  The findings of this meta-analysis differ 
from the results from Hu and Cassano (2000) analysis of NHANES II data with respect to 
vitamin E.  One possible explanation for this discrepancy is that Hu and Cassano used a 
general assessment of lung function and the authors of this meta-analysis were looking 
specifically at studies that measured asthma outcomes.   
While most of the evidence linking certain dietary factors to asthma is taken from 
observational studies, some interventions have investigated the effects of nutrients and 
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food components on asthma.  Tecklenburg and colleagues (2007) conducted a 
randomized, placebo-controlled cross-over supplementation study to evaluate the effect 
of a high-dose vitamin C supplement (1500 mg daily) on exercise-induced asthma 
symptoms in adult asthmatic subjects.  Subjects who received vitamin C had significant 
reductions in their post-exercise drop in forced expiratory volume compared to subjects 
receiving placebo (Tecklenburg et al., 2007, 1770-1778).  In a separate study, Nadi and 
colleagues (2012) designed a double-blinded, placebo-controlled parallel-arm trial 
involving 60 adult asthmatic patients to assess the effect of a 1000 mg vitamin C 
supplement on severity of asthma symptoms assessed by spirometry.  At the end of a 
month-long trial, leukocyte vitamin C had significantly increased in the supplement 
group, but no benefit of vitamin C was seen in spirometry parameters (Nadi et al., 2012, 
233-238).  Writing for the Cochrane collaborative, Kaur and colleagues (2009) reviewed 
the effectiveness of vitamin C supplementation as a treatment for asthma in randomized 
controlled trials.  Only 9 mostly small studies met the inclusion criteria, yielding a total 
of 330 subjects.  The authors concluded that there is insufficient evidence to recommend 
vitamin C as a treatment for asthma at the current time (Kaur, Rowe and Arnold, 2009).   
Respiratory Viruses and Asthma.  Early childhood upper respiratory viral 
infections have been strongly implicated in the etiology of asthma although the question 
of whether childhood respiratory viral infections cause asthma is still a matter of 
discussion in the literature.  In support of this hypothesis, HRV infection is generally 
limited to the upper respiratory tract, but can cause lower respiratory infection in 
vulnerable populations such as infants and small children.  Lower respiratory infection in 
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infancy has been associated with later development of asthma (Kim and Gern, 2012, 116-
121).  Recurrent lower respiratory viral infections may damage developing lungs and 
promote over-sensitization of the immune system that leads to the development of 
asthma.  However, it is unclear whether there is a separate predisposing factor to both 
asthma and severe childhood viral infections or whether the changes in the lung tissue 
that result from chronic lower respiratory infections can be a precipitating cause of later 
development of asthma (Kim and Gern, 2012, 116-121).   
While the contribution of early rhinovirus infection in children to the later 
development of asthma is still a matter of debate, it is well accepted that HRV infection 
in asthmatic individuals can lead to potentially serious asthma exacerbations.  HRV 
infection increases asthma exacerbations through a variety of mechanisms.  HRV has 
been shown to increase the proinflammatory response of airway smooth muscle in vitro 
(Oliver et al., 2006, 71).  Human airway smooth muscle cells were isolated from both 
asthmatic and non-asthmatic volunteers by Oliver and colleagues (2006) and 
experimentally infected with HRV.  The researchers assessed the inflammatory response 
of asthmatic and normal respiratory smooth muscle using ICAM-1 cell surface 
expression, cytokine production and IL-6 transcription.  Cultured respiratory smooth 
muscle cells from asthmatic volunteers exhibited a distinct HRV-specific inflammatory 
response compared to cells from non-asthmatic subjects.  Cells from asthmatic subjects 
secreted significantly more IL-6 than cells from non-asthmatic subjects.  Additionally, 
IL-6 transcription was under different regulatory control, with the two cell groups 
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responding differently to the same experimental stimulus for IL-6 production (Oliver et 
al., 2006, 71).  
HRV infection also affects epithelial cell cultures derived from asthmatic patients 
differently than epithelial cells derived from normal individuals.  Wark and colleagues 
(2005) compared the innate immune response of bronchial epithelial cells derived from 
normal and asthmatic volunteers in vitro during experimental infection with HRV.  Cells 
derived from asthmatic patients had diminished apoptotic response compared to cells 
derived from normal volunteers.  This diminished response supported higher rates of viral 
replication and promoted a higher over-all viral load.  An important factor in the 
apoptotic response to viral infection is interferon-β, which was observed to be deficient in 
the cells from asthmatic patients.  The normal apoptotic response was restored when 
interferon beta was added to the culture medium (Wark et al., 2005, 937-947).   
Asthma and ICAM-1.  ICAM-1 expression is elevated in individuals with asthma.  
A number of studies have replicated evidence for elevated ICAM-1 in asthmatics through 
a variety of experimental techniques.  In an investigation of a dietary antioxidant 
supplement and markers of inflammation, Horvathova and colleagues (2001) incubated 
human umbilical endothelial cells with whole blood taken from healthy and asthmatic 
donors and measured the resultant ICAM-1 expression using flow cytometry.  Induced 
ICAM-1 expression was 4.7-fold greater in asthmatics versus healthy controls 
(Horvathova, Jahnova and Gazdik, 2001, 17-30). 
Asthmatic individuals have a higher level of ICAM-1 expression in nasal 
epithelium than non-asthmatic study participants.  Bianco and colleagues (2000) recruited 
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13 volunteers with atopic asthma and 11 non-atopic, apparently healthy controls for a 
study aimed at characterizing ICAM-1 expression.  The authors evaluated the response of 
ICAM-1 expression to both grass pollen allergen and HRV infection, which are common 
environmental triggers for asthma exacerbation.  Subjects were non-smokers who were 
not currently using steroidal nasal sprays and who did not have a recent history of a cold. 
The study participants supplied specimens in the form of nasal brushings.  Three 
asthmatic patients provided nasal polyp biopsy specimens.  Nasal epithelial cells were 
cultured and surface ICAM-1 expression was evaluated using immunoenzymatic labeling 
protocol and semiquantitative scoring by a blinded, independent observer (Bianco et al., 
2000, 339-345).   
The baseline ICAM-1 expression of the asthmatic study participants was 
significantly greater than healthy controls.  Exposure to clinically relevant allergens 
significantly increased ICAM-1 expression in nasal epithelium taken from asthmatic 
participants, but had no effect on healthy controls.  Nasal polyp biopsy specimens 
expressed ICAM-1 at a very high rate.  The amount of ICAM-1 expression in these cells 
did not increase in response to allergen exposure.  In vitro infection with HRV was 
performed on nasal epithelial cells from healthy controls and on epithelial cells from 
nasal polyp biopsy.  Cells from healthy controls showed an increased ICAM-1 expression 
following HRV infection, but nasal polyp biopsy cells did not.  Given that the nasal polyp 
epithelial cells showed a marked elevation in ICAM-1 expression relative to cells from 
both asthmatic and healthy study participants and did not respond to stimulus from 
allergen exposure or HRV infection, the authors speculated that nasal epithelial cells 
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taken from nasal polyps might already be expressing ICAM-1 at a maximal rate (Bianco 
et al., 2000, 339-345). 
Individuals with asthma have significantly higher levels of circulating sICAM-1 
than non-asthmatic individuals.  Ciebiada and colleagues (2011) evaluated the 
relationship of plasma sICAM-1 to asthma and allergy in an observational study.  In total, 
192 volunteers participated in this study.  Subjects were divided into groups based on 
allergy and asthma status as follows: atopic asthma (63), non-atopic asthma (27), allergic 
rhinitis (64), non-allergic rhinitis (17), and healthy control (21).  Recent infection, 
smoking or serious comorbid health conditions were among the exclusion criteria.  Study 
measures included detailed medical history, skin prick tests for allergy, pulmonary 
function tests, asthma symptom score as well as serum sICAM-1 measured by ELISA.  A 
portion of study participants in both asthma groups were taking corticosteroid drugs for 
management of asthma symptoms (Ciebiada, Gorska-Ciebiada and Gorski, 2011, 660-
666).  Serum sICAM-1 level for the two groups of asthmatic participants was similar and 
was significantly higher than other study groups.  The two rhinitis groups were similar to 
each other and had serum sICAM levels that were intermediate to the asthmatic groups 
and to the healthy control (Ciebiada, Gorska-Ciebiada and Gorski, 2011, 660-666).  The 
combined observations of several studies indicating that asthmatic individuals express 
higher levels of both ICAM-1 and sICAM-1 than non-asthmatic individuals is consistent 
with the pathophysiology of chronic and acute inflammation associated with asthma 
(Ciebiada, Gorska-Ciebiada and Gorski, 2011, 660-666).  
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CHAPTER 3 
METHODS 
Subject Selection 
Asthmatic men and women aged 18 to 65 were recruited from a university 
community for participation in this pilot study.  Volunteers were solicited through e-mail 
using departmental ListServ and flyers distributed throughout the university campus.  
Individuals who responded to recruiting advertisements were directed to an online survey 
to determine if they met the medical history, dietary and physical activity requirements 
for study participation (Appendix C).  Eligible individuals were contacted by e-mail to 
schedule an initial study visit. 
Subjects were excluded from study participation for regular oral or intranasal 
steroid use or for daily use of dietary supplements containing more than 60 mg of vitamin 
C.  Subjects using inhaled steroidal and non-steroidal asthma medications were eligible to 
participate.  Actively training endurance athletes or individuals engaged in significant 
vigorous structured exercise on five or more days per week were also excluded.  Subjects 
who felt ill with symptoms consistent with a cold as assessed by participant interview 
were not eligible to start the trial.  This study has been approved by Arizona State 
University’s Institutional Review Board and all participants provided written informed 
consent prior to enrollment in the study (Appendix A).   
Study Design 
This 18-day pilot study followed a randomized, double-blinded, placebo-
controlled parallel arm design.  Participants were required to appear at the Arizona State 
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University nutrition laboratory facility on the Downtown Phoenix campus for a total of 4 
visits; 1 screening visit and 3 study visits as described in the study timeline (Appendix 
B).  Participant height, weight, nasal lavage and postprandial blood sample (no food or 
drink except water within the last 5 hours) was obtained during the initial screening visit.  
Participants also completed a Rapid Eating Assessment for Participants questionnaire 
(REAPS), Medical History Questionnaire, a food frequency questionnaire to assess 
dietary vitamin C intake, WURSS-21 and Asthma Daytime Symptom Diary Scale 
(DSDS).   
Subjects who meet the inclusion criteria were stratified by age, gender and serum 
vitamin C level and were randomized to either the experimental group or control group.  
The experimental group received a 500mg vitamin C capsule twice daily (morning and 
evening) for a total of 1000mg of vitamin C daily while the control group received a 
wheat flour placebo capsule, identical in appearance to the vitamin C capsule, twice 
daily.  Subjects in both groups were instructed to avoid drinking fruit juices during the 
18-day study period.   
Study visits involving collection of a fasting blood sample were scheduled in the 
morning, between 7:00 and 9:00 am.  At the first study visit, all participants were given a 
booklet containing a study calendar with a daily check-list and copies of the WRSS-21 
and DSDS instruments to record daily cold and asthma symptoms.  Study participants 
also received either supplement or placebo, each in opaque packaging marked with the 
subject number based on randomization to either control or experimental group.  
Participants were instructed to begin taking the capsules twice daily, beginning the 
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morning after leaving the nutrition laboratory.  Participants were asked to return in 4 days 
(study day 4) to provide a nasal lavage sample.   
On day 18 of the study, post-intervention measures including fasting blood 
samples (no food or beverages aside from water for 8 hours) and nasal lavage specimens 
were collected, along with study booklets and remaining supplement or placebo capsules.  
Participant compliance with study protocol was assessed by reviewing study calendar 
check list completion, counting remaining capsules, and by evaluating serum vitamin C 
levels. 
The primary outcome measure of this study was sICAM-1 in nasal lavage.  
Secondary outcome measures included serum sICAM-1, serum histamine and cold and 
asthma symptoms assessed by questionnaire.   
Nasal Lavage Collection 
Nasal lavage was performed following the technique described by Winther and 
colleagues (2002).  Briefly, the subject’s head was placed in a hyperextended position 
and 5 ml of isotonic saline was instilled into each nostril and retained for 5 to 10 seconds.  
The saline was then expelled through the nose into a cup by tipping the head forward 
over a collection container.  Samples were centrifuged to remove mucus contamination 
and stored at -80°C for up to 6 months.  Samples were subjected to no more than 2 
freeze-thaw cycles prior to analysis.  Study participants provided nasal lavage specimens 
on three occasions during the study period.  
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Laboratory Analyses 
sICAM-1 was measured in both nasal lavage and serum using a sandwich 
enzyme-linked immunosorbent assay technique with a commercially available kit 
following manufacturer’s protocol (Invitrogen Corporation, Camarillo, CA).  Protocol is 
available at http://tools.lifetechnologies.com/content/sfs/manuals/KHS5411_revA11.pdf.  
The sensitivity for detection of sICAM-1 in plasma was 0.33 ng/mL.  The manufacturer’s 
expected value in serum was estimated in 50 healthy volunteers as 230.3 ± 47.4 ng/mL. 
Serum histamine was quantitatively acylated and analyzed using a commercially 
available competitive enzyme-linked immunosorbent assay (ALPCO Diagnostics, Salem, 
NH).  Manufacturer’s protocol can be accessed at www.alpco.com/pdfs/17/17-hishu-
e01.pdf.  The sensitivity for detection of histamine in plasma was 0.12 ng/mL, with an 
expected range of <1 ng/mL in healthy adults.   
Plasma vitamin C was assessed using the 2,4-dinitrophenylhydrazine technique 
(Jacob, Skala and Omaye, 1987, 818-826).  Immediately following specimen collection, 1 
ml aliquots of plasma were mixed with 1 ml of ice-cold 10% trichloroacetic acid and 
centrifuged (3500 x g, 0˚C).  Supernatants were stored at -80˚C and analyzed for vitamin 
C concentration within 7 days of specimen collection according to protocol (Appendix 
E).  Subjects provided blood samples for vitamin C assessment at the screening visit and 
on study day 18.  Blood samples for determination of sICAM-1 and histamine 
concentration were collected on study day 1 and study day 18.  
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Survey Measures 
Wisconsin Upper Respiratory Symptom Survey—21.  The Wisconsin Upper 
Respiratory Symptom Survey-21 (WURSS-21) is a validated tool for assessing the 
symptoms of the common cold (Barrett et al., 2009, 76-96).  The instrument consists of 
21 questions that evaluate symptom severity, functional impairment and global illness 
severity.  The questions are evaluated on a magnitude scale with a score of 0 
corresponding to the absence of symptoms and 7 indicating the most severe symptoms.  
The questionnaire is scored by summing the ratings from the first and second sections for 
an assessment of symptom severity and functional impairment respectively, and summing 
the scores of all sections for a global assessment of illness severity.  A higher numerical 
score corresponds to greater severity of cold symptoms.  A cold was defined as reported 
in previous publications (Johnston, 2014, 2572-2583).  A study participant was 
considered to have a cold when upper respiratory symptoms reported on the WURSS-12 
yielded a cold symptom score of 5 or greater on the first 10 questions of the survey.  This 
score represents any combination of the presence of several mild symptoms, moderate 
and mild symptoms together or at least one symptom of moderate or greater severity.  A 
single cold episode was defined as a period of consecutive days with a cold symptom 
score greater than or equal to 5.  An episode was counted as a single cold if a period of 
three or fewer days with symptom scores less than 5 separated two days with a cold 
symptom score of 5 or greater.  This measure was completed daily by the subjects during 
the study period. 
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Asthma Daytime Symptom Diary Scale.  The Daytime Symptom Diary Scale 
(DSDS) is a validated questionnaire used to assess frequency and inconvenience of 
asthma symptoms (Santanello et al., 1997, 646-651).  The survey instrument consists of 
four questions that assess symptom severity and degree of interference with daily 
activities using a seven-point scale representing the magnitude of symptoms.  Asthma 
symptom scores are calculated as the mean score of the four survey questions.  This 
measure was completed daily by the subjects during the study period. 
Statistical analysis  
All data is reported as means ± SD.  Data analysis was performed using IBM 
SPSS Statistics release 21.0.0 (IBM Corporation, Armonk, New York).  Data was tested 
for normal distribution and log10-transformed to achieve normality when necessary.  
When parametric tests were utilized, outliers greater than three standard deviations from 
the mean were excluded from analysis.  Non-parametric tests were used for all data that 
were not normally distributed.  Statistical significance is indicated by p values less than 
or equal to 0.05.  Blinded conditions were maintained until all data was tabulated and 
prepared for statistical analysis. 
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CHAPTER 4 
RESULTS 
Baseline Characteristics   
Rolling recruitment took place from April to June of 2013 with subjects 
completing the 18-day study from May to July of 2013.  Of the 56 survey respondents 
who were screened for study participation, 12 were disqualified for failing to meet 
inclusion criteria and 44 were contacted to schedule a screening appointment (Figure 1).  
Among 44 initially qualified respondents, 31 individuals declined further participation 
and 13 volunteers were enrolled in the study, five of whom were men.  The volunteers 
were screened, stratified by age, gender, and plasma vitamin C concentrations and 
randomly assigned by coin toss to either the placebo group (PLC) or the vitamin C group 
(VTC).  Of the 13 initially enrolled subjects, one subject who had been randomized to the 
VTC group dropped out of the study.  A second subject who had been randomized to the 
PLC group was excluded from some analysis due to failure to complete study 
questionnaires and failure to provide a nasal lavage specimen on study day 4.  Of the 
study participants who completed the trial, 6 subjects were in the VTC group and 6 were 
in the PLC group.   
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The groups did not differ significantly in gender, medication use, age, BMI, body 
fat percentage, REAP-S diet quality score, physical activity (METS/week) or plasma 
vitamin C concentration at baseline (Table 1).  The participants ranged in age from 22 to 
55 years although the mean age was similar in both groups (30.5±9.6 in VTC and 
33.8±11.8 in PLC).  The current recommended dietary allowance (RDA) for vitamin C as 
set by the National Institutes of Medicine Food and Nutrition Board (2000) is 90 mg/day 
for non-smoking men and 75 mg/day for non-smoking women aged 19 years and older. 
Baseline mean dietary vitamin C intake in both groups exceeded the RDA levels for age 
and gender.  On average, study participants’ baseline dietary vitamin C intake was 3.5 
times greater that the RDA level for women and 1.2 times greater that the RDA level for 
men.  The US age-adjusted mean plasma vitamin C for adults aged 20 years or older has 
been reported elsewhere as 86.2 mg/dL (Schleicher et al., 2009, 1252-1263).  Baseline 
plasma vitamin C for both the VTC and PLC groups was lower than the national average. 
 
Figure 1.  Subject Recruitment 
56 responses to 
recruiting advertizement
12 respondents failed to 
meet inclusion criteria
44 respondents contacted 
to schedule initial study 
meeting
31 respondents declined 
further participation
13 participants enrolled  
(7 VTC, 6 PLC)
1 participant (VTC) 
dropped out
1 participant (PLC) 
failed to complete sutdy 
packet and day 4 NL 
11 subjects (6 VTC, 5 
PLC) completed study
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To compare asthma medication use between VTC and PLC groups, subjects were 
divided into two categories based on the type of medications used to treat asthma.  
Subjects who used daily inhaled steroidal medications to control asthma were placed in 
one category (“daily”).  In this study, all subjects who used daily preventative treatment 
also reported using bronchodilator medications as needed to treat asthma exacerbation, 
i.e. rescue inhaler.  Subjects who did not use a daily preventative treatment but reported 
using only a rescue inhaler as needed or who reported using no prescription medications 
were placed in a second category (“as needed”).  A Chi-square test for independence 
indicated no significant association between group assignment (VTC or PLC) and asthma 
medication use, χ2=0.066, p=0.797. 
Table 1.  Baseline Characteristics by Group a  
 
Characteristic Vitamin C (n=7) Placebo (n=6) p 
Gender (male/female) 3/4 2/4 0.725 b 
Asthma Medication Use 
(daily/as needed) 
3/4 3/3 0.797 b 
Age (years) 30.5±9.6 33.8±11.8 0.518  
BMI (kg/m2) 26.5±3.7 23.8±5.5 0.199 
Body Fat (%) 31.7±10.4 24.9±8.2 0.086 
Dietary Vitamin C  (mg/day) 171.8±93.3 239.2±279.5 0.775 
Diet Quality Score 30.6±4.1 30.8±3.3 1.00 
METS (kcal·kg-1·week-1) 39.4±39.7 52.2±34.3 0.520 
Plasma Vitamin C (mg/dL) 0.52±0.20 0.59±0.26 0.568 
a. Values are mean ± SD with the exception of gender.  There were no significant 
differences between groups (p>0.05, Mann-Whitney U test).  
b. Chi-Square test 
 
Biochemical Measures 
There were no significant differences between VTC and PLC groups in any 
plasma biochemical indices (Table 2).  Both the VTC and PLC groups showed an 
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increase in plasma vitamin C level on study day 18 compared to baseline.  A larger, but 
not significant increase was measured in the VTC group (0.33±0.59 vs. 0.10±0.22, 
p>0.05).  Plasma histamine concentrations showed a slight, non-significant increase in 
both groups compared to baseline (VTC group 1.47±3.02 vs. PLC group 1.89±4.11).  
Plasma sICAM-1 concentrations decreased from baseline for both groups, however the 
difference between groups was not significant (VTC group -23.07 ±9.32 vs. PLC group -
30.85±10.76, p>0.05).   
There were no significant mean differences between groups in nasal lavage 
sICAM-1 (Table 3).  The mean nasal lavage sICAM-1 concentration was lower for the 
VTC group compared to the PLC group on study day 4 (-1.51±0.76 vs. 3.33±2.81, 
p>0.05), although these differences were not significant.  The mean nasal lavage sICAM-
1 concentrations were similar for both groups on day 18 (1.58±0.95 vs. 1.72±0.80, 
p>0.05).  There was a strong, significant correlation between baseline plasma sICAM-1 
and nasal lavage sICAM-1 on study day 18 (Spearman’s rho =0.637, p=0.026) for both 
groups. Nasal lavage sICAM-1 levels at baseline were significantly correlated with nasal 
lavage baseline sICAM-1 on study day 18 (Spearman’s rho =0.753, p=0.005).  Other 
correlations between nasal sICAM-1 measures and plasma sICAM-1 measures were not 
significant. 
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Table 2.  Plasma biochemical indices at day 1 and day 18 a 
 Day 1 Day 18 ∆ Day 1 vs Day 18 p 
b 
Plasma Vitamin C (mg/dL)     
VTC 0.52±0.20 0.90±0.47 0.33±0.59 0.873 
PLC 0.59±0.26 0.69±0.11 0.10±0.22  
Plasma Histamine (ng/mL)     
VTC 1.04±0.31 2.51±3.28 1.47±3.02 0.749 
PLC 1.41±0.82 3.30±4.42 1.89±4.11  
Plasma sICAM-1 (ng/mL)     
VTC 88.67±9.14 66.4±9.95 -23.07±9.32 0.262 
PLC 91.50±19.26 60.65±9.94 -30.85±10.76  
a. VTC (Vitamin C group) n=6, PLC (Placebo Group) n=6, values are mean ± SD 
b. There were no significant differences between groups (p>0.05, Mann-Whitney U test). 
 
Table 3.  Nasal lavage sICAM-1 at day 1, day 4 and day 18 a 
 Day 1 Day 4 
b
 Day 18 ∆ Day 1 vs 
Day 4 
p 
c
 ∆ Day 1 vs 
Day 18 
p 
c 
VTC 2.39±1.24 1.51±0.76 1.58±0.95 -0.88±0.95 0.223 -0.93±1.07 0.873 
PLC 2.63±0.67 3.33±2.81 1.72±0.80 0.63±2.65  -0.91±0.53  
 
a. Values are mean ± SD, VTC (Vitamin C group) n=6, PLC (Placebo Group) n=6 for all 
measures except Day 4 
b. VTC n=6, PLC n=5 for  Day 4 only 
c. There were no significant differences between groups (p>0.05, Mann-Whitney U test ) 
 
Survey Measures 
There were no significant differences between VTC and PLC groups in cold or 
asthma symptoms (Table 4).  Cold symptoms were assessed daily using Wisconsin 
Upper Respiratory Symptom Survey-21 (WURSS-21) (Figure 2).  Total cold symptom 
score was calculated as the sum of 18 days.  The total cold symptom score for the VTC 
group was slightly greater than for the PLC group, but this difference was not significant 
(VTC 64.2±66.3 vs. PLC 48.4±44.3, p >0.05).  Number of colds and total cold days were 
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similar in both groups (Number of colds VTC 0.5±0.5 vs. PLC 0.8±0.8, total cold days 
VTC 3.3±5.0 vs. PLC 2.8±3.7, p >0.05).   
Table 4.  Analysis of Cold and Asthma Symptoms Over 18 Days a, b 
 VTC (n=6) PLC (n=5) p 
Total Cold Symptom 
Score c 
64.2±66.3 48.4±44.3 0.602 
Number of Colds c 0.5±0.5 0.8±0.8 0.545 
Cold Days d 3.3±5.0 2.8±3.7 0.848 
Total Asthma Symptom 
Score e 
12.9±11.8 17.9±10.5 0.602 
    
a. VTC (Vitamin C group) n=6, PLC (Placebo Group) n=5 
b. Values are mean ± SD.  There were no significant differences between groups 
(p>0.05, Mann-Whitney U test). 
c. Colds assessed using WURSS-21; units are arbitrary measure of magnitude of 
symptoms 
d. Assessed using WURSS-21; Number of days where cold symptom score was >5 
(definition of “cold”) 
e. Asthma symptoms assessed using DSDS; units are units are arbitrary measure of 
magnitude of symptoms 
 
Participants reported asthma symptoms daily during the study period using 
Daytime Symptom Diary Scale (DSDS) (Figure 3).  The DSDS consists of 4 questions 
that assess frequency, severity and impact of asthma symptoms on daily activities where 
each item is rated on a seven-point scale from 0 (no symptoms) to 6 (very severe).  Daily 
asthma symptom scores were calculated by taking the mean daily score of survey 
questions.  Total asthma symptom score was calculated as the sum of 18 daily scores.  
Scores are arbitrary units representing a magnitude of symptom severity.  Total asthma 
symptom scores were lower for the VTC group compared to the PLC group; however this 
difference was not significant (VTC 12.9±11.8 vs. PLC 17.9±10.5, p> 0.602).  There was 
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no significant correlation between total cold symptom score and total asthma symptom 
score, or between survey measures and biochemical measures.  
 
 
 
Figure 2.  Comparison of daily cold symptom scores by group 
a. Colds assessed using WURSS-21, units are arbitrary measure of magnitude of  
symptoms.  VTC (Vitamin C group) n=6, PLC (Placebo Group) n=5 
Figure 3.  Daily asthma symptom score 
a. Daily asthma symptoms assessed using Daytime Symptom Diary Scale.  Units are 
 arbitrary measure of magnitude of symptoms. VTC (Vitamin C group) n=6, PLC 
(Placebo Group) n=5 
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Compliance Measures 
Participant compliance with study protocols was high.  Overall, there was a 
95.2% compliance rate for subjects taking pills as determined by the number of pills 
returned at the final study visit and self-report of missed doses.  With the exception of 
one subject who failed to return the study questionnaire packet, 98.9% of daily study 
questionnaires within the study packet were completed. 
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
Major Findings 
 No mean comparisons reached a level of significance in this study.  It is possible 
that these findings are related to a genuine lack of response in the experimental group, or 
it may be related to other factors, such as the small number of study participants in the 
VTC and PLC groups.  Several observations from this trial support the conclusion that 
sample size was too small to detect an effect from the intervention, if an effect existed.  
For many measures in this study, the standard deviation was large, indicating high inter-
individual variability.  Given that the number of subjects in both the VTC and PLC 
groups was 6 for most measures, individual variation may have exerted undue influence 
in the analysis. 
Prior investigations into plasma vitamin C level in response to vitamin C 
supplementation informed the design of the current study with respect to level of 
supplementation and expected participant response (Johnston, 1999, 71-77; Johnston and 
Cox, 2001, 623-627; Johnston 2014, 2572-2583).  As expected, the VTC group showed a 
mean increase in plasma vitamin C level on study day 18 compared to baseline (n=6, 
0.90±0.5, ∆ 0.33±0.6).  This finding agrees with a high rate of participant compliance in 
taking supplements. However, participants in the PLC group also showed a small 
increase in plasma vitamin C level over the study period (n=6, 0.69±0.1, ∆ 0.10±0.2) and 
a comparison of means revealed no significant difference between groups (p=0.873). This 
result is not consistent with the expectation that plasma vitamin C level would be 
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significantly greater for subjects receiving 1000 mg of vitamin C daily than for subjects 
receiving a wheat flour placebo. Subjects in both groups were instructed to not to make 
any changes to their usual dietary habits over the course of the 18-day study period, with 
the exception of avoiding fruit and vegetable juices. The observation that the mean 
plasma vitamin C level increased the PLC group suggests that subjects did alter their 
diets somewhat, even if these changes were not intentional.  
Subjects in this study had a mean plasma vitamin C level that was lower than the 
US age-adjusted mean (VTC + PLC 0.55 mg/dL vs. US 0.86 mg/dL) (Schleicher et al., 
2009, 1252-1263).  This agrees with findings of previous studies that report an 
association between low plasma vitamin C status and asthma.  Interestingly, subjects in 
this study had low plasma vitamin C levels despite reporting a relatively high dietary 
intake of vitamin C. Other authors have reported that low dietary vitamin C intakes were 
associated with the greatest risk of having asthma (Allen, Britton and Leonardi-Bee, 
2009, 610). This group of study participants appears to have adequate dietary vitamin C 
intake, but lower than average vitamin C status.  
Plasma sICAM-1 measures were not significantly different between groups at the 
end of the study period. Based on findings from Rayment and colleagues (2003) and 
others, plasma sICAM-1 was expected to be lower in the VTC group than the PLC group 
at the end of the study.  It is possible that subject plasma vitamin C levels did not increase 
enough in the VTC group to induce a change.  There is no established reference range for 
sICAM-1 in plasma.  The manufacture’s kit provides an expected value of 230.3 ± 47.4 
ng/mL, based on a sample of 50 apparently healthy volunteers.  Other investigators who 
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measured plasma sICAM-1 using ELISA report a wide range of values from 120 ng/mL 
to a 507.6 ng/mL in both healthy and diseased study populations.  Canales and colleagues 
(2011) reported a baseline value of 507.6 ± 165.0 ng/mL among study participants who 
were at high risk for developing heart disease. Rayment (2003) and colleagues observed 
baseline levels of plasma sICAM-1 of 470±30 ng/mL among otherwise healthy subjects 
with lower than average serum vitamin C.  Witkowska (2004) reviewed a number of 
studies measuring sICAM-1 in plasma in relationship to various disease states.  In one of 
the studies reviewed by Witkowska, patients with angina had a baseline plasma sICAM-1 
of 120±10 ng/mL.  Another study reported a baseline plasma sICAM-1 of 373.27±183.5 
ng/mL among heart transplant patients with graft rejection. The sICAM-1 values 
measured in the present study range from 64.4 to 121.6 ng/mL, with a mean value 89.89 
ng/mL.  It may be that these values are not directly comparable between studies due to 
variation in laboratory methods.  
Based on the hypothesis that sICAM-1 levels in the nasal epithelium would be 
related to sICAM-1 levels in plasma, the sICAM-1 level in nasal lavage was expected to 
decrease in the VTC group following vitamin C supplementation. The mean nasal lavage 
sICAM-1 level was lower in the VTC group on study day 4 (-1.51±0.76 vs. 3.33±2.81, 
p>0.05), but the difference was not significant between VTC and PLC groups.  Because 
of dilution from lavage fluids, nasal sICAM-1 levels were expected to be lower than 
plasma levels, and this expectation was met. Assessing sICAM-1 in lavage fluids has 
been previously reported in the literature.  For example, Marguet and colleagues (2000) 
assessed sICAM-1 by ELISA in bronchoalveolar lavage specimens obtained from 
 54 
children with airway disease.  The range of values in this study was fairly wide, but the 
median value was 106 ng/mLwith an interquartile range of 94-257 ng/mL.  Winther and 
colleagues (2002) measured nasal lavage sICAM-1 in a study of experimental HRV 
infection in healthy volunteers.  Since the authors only reported their data for nasal 
lavage sICAM-1 graphically, exact values were not available. However, it is clear that 
there was a wide variation in sICAM-1 levels as the data was plotted on a logarithmic 
scale from 1 to100 ng/mL.  The mean baseline value was between 1 and 10 ng/mL in 
Winther and colleagues’ report.  The mean baseline nasal lavage ICAM-1 value in this 
study was 2.5 ng/ mL, and appears generally similar to the observations made by Winter 
and colleagues. In this study plasma sICAM-1 level at baseline was significantly 
correlated with nasal sICAM-1 on study day 18.  This suggests a relationship between 
endothelial shedding of ICAM-1 detected in blood and epithelial shedding of ICAM-1 
detected in nasal lavage.  
 
Limitations 
This study has a number of limitations. One limitation is small sample size.  
Power analysis could not be completed for this research because the primary outcome 
measure of this study, change in sICAM-1 concentration in nasal lavage in response to a 
dietary intervention, has not been previously reported in the literature. It was one aim of 
this study to collect data to make power analysis calculations possible for future studies.    
Another limitation of this research is reliance on subjective self-report of symptom 
severity for both asthma and cold symptoms.  Although an objective measure of asthma 
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symptoms exists, i.e. spirometry, pulmonary function tests, these measures were not 
included as outcomes in this study. An objective measure of HRV infection could have 
contributed to the strength of this study, however there is no clinically useful diagnostic 
test to easily identify HRV infection and a validated survey was used to identify 
presumptive colds based on symptoms. The subjects in this study were free-living 
volunteers and many measures relied on participant self-report without the ability to 
independently verify participant statements. Subjective measures, such as ratings of 
perceived symptom severity can vary widely from individual to individual.  
Strengths   
Strengths of this study include a robust experimental design.  As a double-blind, 
placebo-controlled parallel arm clinical trial, this study was designed to address cause 
and effect research questions.  Significant care was taken to maintain blinded conditions 
throughout the investigation.  The study was not un-blinded until all data were scored and 
prepared for statistical analysis. Asthma patients, the target population for this study, 
have been identified as a group with poor vitamin C status compared to the general 
population.  The asthmatic participants in this study had lower baseline plasma vitamin C 
than the general population.  With minor exceptions, subjects appeared to have very good 
compliance with study protocols, taking 95.2% of study capsules and completing 98.9% 
of study questionnaires. 
Conclusion and Application 
This study was designed as a preliminary feasibility trial to assess the impact of 
vitamin C supplementation on sICAM-1 in nasal lavage and plasma of asthmatic study 
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participants. The primary end point of this study, change in sICAM-1 in nasal lavage, has 
not previously been measured in response to a dietary intervention. While the power of 
the statistical analysis in this study was limited related to small sample size and sample 
variability, a number of interesting, if not significant conclusions can be reached. The 
data collected in this study will provide a useful foundation for future work and enable a 
more refined approach to future studies. Although findings in this study did not reach the 
level of significance, some speculations are possible from the study results.  For example, 
the greatest mean difference (not significant) between VTC and PLC groups appeared in 
sICAM-1 nasal lavage from study day 1 to day 4. This suggests that future study designs 
could be shortened while still capturing the physiological response to vitamin C 
supplementation. 
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Enrollment 
 
 
Randomization 
 
VTC Group VTC Group 
PLC Group PLC Group 
 
 
 
 
 
Study Visit 1  
• Informed 
consent 
• NL 
• Blood 
Collection 
• Anthropometric 
Data 
• DSDS REAPS 
• WURSS-21 
• Medical history 
• Vitamin C FFQ 
Study Visit 2 
• Blood 
Collection 
• NL 
• Study booklet 
distributed 
• Supplement or 
Placebo 
distributed 
Study Visit 3 
• NL 
 
Study Visit 4 
• Blood 
collection 
• NL 
• Study 
booklet 
collected 
• Vitamin C 
FFQ 
• Remaining 
supplement 
or Placebo 
Collected 
 
 
 
VTC  Vitamin C Group, experimental arm 
PLC   Placebo Group, control arm 
NL  Nasal Lavage 
DSDS  Daytime Symptom Diary Scale, asthma symptom questionnaire  
REAPS Rapid Eating Assessment for Participants short form, diet quality 
assessment 
WURSS-21  Wisconsin Upper-Respiratory Symptom Survey-21, assessment for cold 
symptoms 
FFQ Food Frequency Questionnaire, assessment of dietary vitamin C intake 
 
  
DAY 1 DAY 4 DAY 18 DAY 0 
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Adults with Asthma Needed for ASU 
Asthma Trial  
  
The ASU Nutrition Program is recruiting adults with doctor-
diagnosed asthma (18-65 years of age).  
  
This 18-day trial will examine whether a dietary supplement 
may improve inflammation and symptoms of asthma. If you 
are willing to provide 3 blood samples and 3 nasal washings, 
and to record respiratory tract symptoms daily for 18 days, 
you may be interested in this trial.   
  
  
To apply for the study, please visit our recruitment 
site: 
https://www.surveymonkey.com/s/ASUAsthmaStudy 
  
 
  
For more information, contact Lindsay Gnant; lstubbs@asu.edu 
or Carol Johnston; Carol.Johnston@asu.esu. 
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ASU Asthma Study Recruitment Survey  
 
*1. Please provide your e-mail address. 
 
*2. Select your gender. 
 Male 
 Female 
 
*3. Has your doctor diagnosed you with asthma? 
 Yes 
 No 
 
*4. Do you currently experience symptoms of asthma? 
 Yes 
 No 
 
*5. Do you currently smoke cigarettes? 
 Yes 
 No 
 
*6. Do you take prescription medications every day to control your asthma? 
 Yes 
 No 
 
*7. Do you use prescription medications (such as an inhaler) to treat your asthma 
symptoms when you have an asthma attack? 
 Yes 
 No 
 
*8. Are you between 18 and 65 years old? 
 Yes 
 No 
 
*9. Do you exercise vigorously over 4 times weekly and/or consider yourself a 
competitive athlete? 
 Yes 
 No 
 Not sure 
 
*10. Do you weigh at least 110 pounds? 
 Yes 
 No 
 Not sure 
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*11. Are you willing to have a small amount of blood taken from an arm vein (<1 
Tablespoon) on 3 occasions during the trial? 
 Yes 
 No 
 Not sure 
 
*12. Are you willing to provide a nasal wash on 3 occasions during the trial? (This entails 
dripping sterile saline solution into both nostrils while your head is tilted back, waiting 
several moments, then tilting the head down and allowing the nasal wash to run into a 
cup.) 
 Yes 
 No 
 Not sure 
 
*13. Are you currently being treated by a physician for a chronic disease or condition 
other than asthma (e.g., cancer, diabetes, arthritis, inflammatory bowel disease, 
heartdisease, hepatitis, etc.)? 
 Yes 
 No 
 
*14. Do you regularly take vitamin/mineral supplements? 
 Yes 
 No 
If yes, please list these supplements. 
 
*15. Are you willing to (1) not drink any fruit or vegetable juice for 18 days and (2) not 
change your diet or activity level for 18 days? 
 Yes 
 No 
 Not sure 
 
*16. Are you willing to record respiratory tract symptoms daily for 18 days? 
 Yes 
 No 
 Not sure 
  
*17. Are you able to come to the ASU Downtown Phoenix Campus on 4 occasions in the 
next several months? (The ASU nutrition laboratories are located at 5th Street and Van 
Buren.) 
 Yes 
 No 
 Not sure    
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Daytime Symptom Diary Scale questions 
 
1) How often did you experience asthma symptoms today? 
0  1  2  3  4  5  6 
None of      All of 
the time      the time 
 
2) How much did your asthma symptoms bother you 
today? 
0  1  2  3  4  5  6 
Not at all      Severely 
bothered      bothered 
 
3) How much activity could you do today? 
0  1  2  3  4  5  6 
More than      Less than 
usual activity      usual activity 
 
4) How often did your asthma affect your activities today? 
0  1  2  3  4  5  6 
None of      All of 
the time      the time 
 
 
Nocturnal Diary Scale question 
 
1) Did you wake up with asthma symptoms.  (This can be awakening in the middle of the 
night or on awakening in the morning)? 
 
❏ No ❏ Once ❏ More than once ❏ Awake "all night" 
 
 
 
 
Daytime Symptom Diary Scale and Nocturnal Diary Scale (developed by N.C. Santanello 
et al.) 
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LABORATORY PROTOCOLS FOR PLASMA VITAMIN C 
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Reagent Preparation:  
Store all reagents under refrigeration prior to use. 
1. Prepare 10% trichloroacetic acid (TCA) solution 
Mass 10 g TCA, add deionized water to a volume of 100 mL 
2. Prepare 5% TCA 
Mass 5 g TCA, add deionized water to a volume of 100 mL 
3. Prepare 9N H2SO4 
Measure 300 mL deionized water, slowly add to a volume of 100 mL 36N 
H2SO4 
4. Prepare 2,4-dinitrophenlylhydrazine, tiourea, copper sulfate (DTC) reagent 
Mass: 0.9 g 2,4-dinitrophenlylhydrazine 
  0.12 g thiourea 
  0.015 g copper sulfate pentahydrate 
Combine in a 50 ml beaker with stir bar, slowly add 30 mL 9N H2SO4 
Stir until dissolved 
5. Prepare ascorbic acid stock solution 
Mass 5 mg ascorbate, add 5% TCA to a volume of 25 mL 
Store 1 mL aliquots at -80°C 
6. Prepare working ascorbic acid solution immediately prior to running assay 
Pipette 500 µL acorbic acid stock solution, add 5% TCA to a volume of 25 
mL 
Specimen Collection: 7 mL lavender top tube 
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Whole blood may be maintained for a short period of time at room temperature on a 
rocker prior to processing. 
Specimen Processing:  
1. Spin down whole blood in a refrigerated centrifuge at 4° C at 2800 RPM for 10 
minutes 
2.  Pipette 2.5 mL 10% TCA into a glass tube, place the tube in ice.  
3. Add 2.5 mL plasma to the tube containing 2.5 mL 10% TCA 
4. Vortex for 10 seconds to mix 
5. Spin down sample in a refrigerated centrifuge at 4° C at 4000 RPM for 20 
minutes. 
6. Divide supernatants into 1.5 mL aliquots and freeze at -80°C immediately 
Assay Procedure: 
1. Prepare 6 ascorbic acid standards in duplicate in glass test tubes according to the 
following table: 
Standard Ascorbic Acid Working Solution (µL) 5% TCA (µL) DTC (µL) 
1 (0 mg/dL) 0 500 100 
2 (0.4 mg/dL) 100 400 100 
3 (0.8 mg/dL) 200 300 100 
4 (1.2 mg/dL) 300 200 100 
5 (1.6 mg/dL) 400 100 100 
6 (2 mg/dL) 500 0 100 
 
2. Prepare samples in duplicate:  
Pipette 500 µL sample and 100 µL DTC reagent into a glass test tube 
3. Cover test tubes to prevent evaporation.  Incubate samples and standards together 
at 37°C for 3 hours. 
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4. Add 750 µL ice cold 65% H2SO4 to each tube. Vortex for 5 seconds after each 
addition. 
5. Incubate at room temperature for 30 minutes 
6. Read absorbance at 520 nm in spectrophotometer, using standard #1 as a blank 
7. Produce a standard curve from using standards 1-6. Plot ascorbic acid 
concentration (mg/dL) on the horizontal axis and absorbance on the vertical axis. 
Use a linear model to produce a line of best fit. Calculate sample ascorbic acid 
concentration in mg/dL from the standard curve.  
